The purpose of this study is to find out the effects of a drug called LBH589 when given to people with recurrent or refractory Hodgkin or Non-Hodgkin's lymphoma. The safety of this drug will also be studied. The participant’s physical state, changes in the size of the tumor, or state of Hodgkin or non-Hodgkin's Lymphoma, and laboratory findings taken while on-study will help the researchers decide if LBH589 is safe and effective.
- Age 18 or over
- Diagnosis of relapse/refractory Hodgkin Lymphoma or NHL
- Lab results within normal limits, unless due to bone marrow involvement with lymphoma
Prior HDAC or valproic acid cancer treatment
Impaired Cardiac or GI Function